Biogen (BSP:BIIB34) Institutional Ownership

: 0.00% (As of Today)

View and export this data going back to 2016. Start your Free Trial

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biogen's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biogen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biogen's Float Percentage Of Total Shares Outstanding is 0.00%.

Biogen Institutional Ownership Historical Data

The historical data trend for Biogen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Historical Data

The historical data trend for Biogen can be seen below:

	2018-08-31	2018-09-30	2018-10-31	2018-11-30	2018-12-31	2019-01-31	2019-02-28	2019-03-31
Institutional Ownership	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

Biogen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BSP:BIIB34) Headlines

No Headlines